.jpeg)
2026-08-10 07:34:19
Cemiplimab is a PD-1 immunotherapy drug used for advanced skin cancers and non-small cell lung cancer. As a biologic agent, it requires strict refrigeration at 2°C to 8°C, protection from freezing, light, and agitation to maintain drug stability and efficacy.
2026-08-10 07:19:45
At the 62nd ASCO Annual Meeting, targeted therapies, ADCs and immunotherapies advanced on three fronts against pancreatic cancer. Phanes Therapeutics' CLDN18.2/CD47 bispecific antibody spevatamig, combined with GnP chemotherapy, showed striking first-line data in metastatic pancreatic cancer, and its innate immunity–enhancing mechanism may break the "cold tumor" dilemma.
2026-08-10 06:59:18
On August 6, 2026, Moderna’s mRNA seasonal influenza vaccine mFLUSIVA became the first mRNA flu vaccine approved by the U.S. FDA for adults aged 50 and older, ushering in a new era of mRNA-based influenza prevention.
2026-08-10 06:51:08
Nintedanib (Ofev) is a multi-target antifibrotic agent approved for IPF, progressive fibrosing interstitial lung diseases, and systemic sclerosis-associated ILD. This article outlines its full therapeutic scope and mechanism of action.
2026-08-10 06:39:28
Belumosudil (Rezurock) is a selective ROCK2 inhibitor approved for chronic graft-versus-host disease. This article explains the expected timeline, efficacy assessment, and realistic goals when treating pulmonary cGVHD.
2026-08-07 07:30:56
Mavacamten is the first cardiac myosin inhibitor targeting the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM). This article reviews its treatment duration, clinical efficacy, head-to-head comparisons with conventional therapies, and long-term management strategies.
2026-08-07 07:13:02
Belzutifan is the first approved hypoxia-inducible factor-2α (HIF-2α) inhibitor, indicated for VHL disease-associated tumors, advanced renal cell carcinoma, and pheochromocytoma/paraganglioma. This article provides a systematic overview of its approved indications, adult and pediatric weight-based dosing, administration guidelines, drug interactions, and safety monitoring requirements to support standardized clinical use.
2026-08-07 06:55:55
Encorafenib is an oral selective BRAF V600 kinase inhibitor used in combination with binimetinib or cetuximab for BRAF-mutant melanoma, metastatic colorectal cancer, and non-small cell lung cancer. This article provides a systematic review of its label highlights, tumor-specific dosing schedules, administration timing, drug interactions, and special population guidance to support standardized clinical use.
2026-08-07 06:49:51
Tazemetostat is the world's first approved oral EZH2 methyltransferase inhibitor, targeting epigenetic dysregulation in follicular lymphoma and epithelioid sarcoma. This article provides a comprehensive overview of its mechanism of action, approved indications, efficacy data, standard starting and maintenance dosing, dose modification protocols, and the critical safety alert regarding its global market withdrawal in March 2026 due to secondary hematologic malignancy risk.
2026-08-07 06:44:53
On August 5, 2026, the U.S. FDA approved Takeda's oral tablet Orzeyful (oveporexton) for adults with Narcolepsy Type 1 (NT1). As the first-in-class selective OX2 receptor agonist targeting the orexin pathway, Orzeyful moves beyond symptomatic relief to address the underlying orexin deficiency, simultaneously improving excessive daytime sleepiness, cataplexy, and disrupted nighttime sleep.
2026-08-06 07:53:13
Alpelisib (Piqray) and inavolisib (Itovebi) both target the PI3Kα pathway in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, yet their approved indications, combination partners, and evidence bases differ. This article compares the two agents across treatment line, clinical evidence, and safety considerations.
2026-08-06 07:40:26
Selumetinib (Koselugo) is the first approved MEK1/2 inhibitor for symptomatic, inoperable plexiform neurofibromas associated with Neurofibromatosis Type 1 (NF1), offering a precision-targeted therapy that reduces tumor volume and alleviates disease-related symptoms in children and adults.
